| NCT06982521 | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | RECRUITING | PHASE3 | 2025-08-26 | 2031-12-31 | 2028-04-30 |
| NCT06789913 | A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation | RECRUITING | PHASE2 | 2025-06-13 | 2031-10 | 2031-07 |
| NCT05759949 | First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors | COMPLETED | PHASE1 | 2023-03-29 | 2025-04-11 | 2025-03-18 |
| NCT05216432 | First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | RECRUITING | PHASE1 | 2021-12-08 | 2027-04-30 | 2027-04-30 |